🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Good luck to UCC Ireland spinout Adiso Therapeutics at the KTI Connect Awards tonight. We sat down with Professor Paul Ross, one of the founders of Adiso Therapeutics, to discuss the history of Adiso Therapeutics & its achievement of being shortlisted for the commercialisation award – bit.ly/3Vlz6TG

KTI Connect awards have just started. Good luck to all those short listed, especially UCC Ireland and APC Microbiome Ireland spin- out company Adiso Therapeutics shortlisted for the Commercialisation Award #ktiawards

UCC Innovation KTI Connect Adiso Therapeutics Kathriona Devereux Great to see Michéal and Kathriona at this important event. We’ll done everyone.

Major milestone alert! We’re thrilled to present data from our Phase 1b MAD study of ADS051 for moderate-to-severe ulcerative colitis this month at #UEG2023 and #ACG2023. More details to come! my_UEG Week 2023 ACG 2023 Annual Scientific Meeting

We’re delighted to welcome Robert Lisicki, an accomplished #biopharma industry executive, to our Board of Directors! Rob’s expertise will be an integral resource as we advance our neutrophil modulator, ADS051, to Phase 2 for #IBD. Learn more: bit.ly/45sz5S3

It’s with great pleasure that we announce positive topline data presented at #ACG2023 from our Phase 1b MAD study of ADS051, a first-in-class, oral, gut-restricted, small molecule neutrophil modulator for #ulcerativecolitis! Read the release: bit.ly/46X4Yn5

Our team was overjoyed to unveil positive topline data from our Phase 1b MAD study highlighting the potential of ADS051 as a safe and effective therapy for #ulcerativecolitis. We’re excited to advance ADS051 in a Phase 2 trial. Learn more: bit.ly/46X4Yn5

We’re excited to participate in the Wells Fargo 2023 Virtual Private Biotech Symposium, fresh off the heels of our positive topline data announcement from our Phase 1b study of ADS051! Connect with us to learn about our great progress. #ulcerativecolitis #inflammatorydisease

We wish a happy Thanksgiving to all, with gratitude for the courageous patients who participated in Adiso clinical trials, as well as our advisors and partners for their guidance and unwavering support. From our team to you, have a healthy and happy #Thanksgiving! #PatientsFirst

Today kicks off Crohn’s & Colitis Awareness Week. Year-round, we are dedicated to advancing research and development of novel therapies for patients with #ulcerativecolitis and other #inflammatorydiseases. Read about our progress: bit.ly/47RLUao #IBDVisible

Adiso is pleased to announce a Precision Immunology collaboration with Geneoscopy investigating therapeutic options for patients with #IBD. Employing #RNA biomarker technology developed by Geneoscopy in conjunction with ADS051. Learn more: bit.ly/3TbtFJ0

Connect with Adiso at #BiotechShowcase in San Francisco next month! Get in touch with us directly at [email protected] or through the partnering platform to schedule a meeting: bit.ly/3thApub #Inflammatorydisease #Ulcerativecolitis #Biotech

From the Adiso team to you, have a safe and happy #holidayseason. As we approach the new year, we’d like to reflect on our 2023 milestones and express gratitude to all who have contributed to our achievements. May your time with friends and family be filled with joy.

発酵食品やヨーグルトに含まれる乳酸菌がストレスへの抵抗力と抑うつ・不安予防に役立つことを示唆する論文。バージニア大学の研究によれば、乳酸菌は免疫機能を調整して気分に影響を及ぼし、抑うつや不安などのメンタルヘルスの予防・治療に役立つ可能性が示された。 (Brain Behavior and Immunity)

We look forward to participating in the virtual Canaccord Genuity Inflammatory Bowel Disease Symposium this Wednesday. Tune in to the “Emerging Novel Targets in IBD” panel to hear Adiso CEO Scott Megaffin discuss our highly differentiated approach to treating #inflammatorydiseases.

Adiso is developing ADS051 to provide patients a new treatment opportunity. We believe this mission is fulfilled by keeping #patientsfirst. Listen to our recent podcast with Rahul Chaturvedi of the Biotech2050 Podcast t.ly/lF_JG #Leadership #IBD #ulcerativecolitis

Interesting: Adiso Therapeutics Adiso Therapeutics researchers present a LPA3 agonist-producing Bacillus velezensis (called ADS024) whose anti-neuroinflammatory properties corrects multiple models of #Parkinsons (& #MultipleSclerosis, #Huntingtonsdisease, #ALS, etc) sciencedirect.com/science/articl…

Interesting: Paras Minhas, MD, PhD et al report inhibition of indoleamine-2,3-dioxygenase 1 (IDO1) & production of kynurenine rescues hippocampal synaptic plasticity & memory function in models of amyloid & tau pathology (via astrocytic metabolic support of neurons) science.org/doi/10.1126/sc…

Team Adiso Therapeutics thrilled with latest ADS024 publication - an oral single strain live biotherapeutic (SS-LBP) This research highlights the potential role of ADS024 for neuroinflammatory conditions #MS #Parkinson #FA #Huntingtons #Patientsfirst #neuroinflammaiton UCC Ireland #GCPR #ALS

"GPCR targeting represents approximately 35% of all approved drugs and account for neurological indications such as ..." A true leap forward in MOA understanding for a biotherapeutic! [LPA3 agonism] #Parkinsons #MultipleSclerosis #Neuroscience